[Evaluation of efficacy of 153Sm-EDTMP in patients with painful bone metastases of breast cancer].
OBJECTIVE
To explore the therapeutic efficacy of 153Sm-EDTMP in treating painful bone metastases from breast cancer.


METHODS
Seventy-six patients with painful bone metastases from breast cancer entered the study and were treated by intravenous administration of 153Sm-EDTMP in two doses.


RESULTS
Overall, 65 of 76 patients (85.52%) experienced prompt pain relief; among them 25 patients (32.89%) felt complete remission and 40 patients (52.63%) met with moderate remission. Follow-up imaging examinations were performed after each course of treatment. Complete metastatic foci disappearance was achieved in 6 cases and partial metastatic foci disappearance or regression was achieved in 16 cases, so the global effective rate was 28.95%. No major adverse effects were observed, and hematological toxicity did not exceed grade 3 in accordance to the World Health Organization criteria.


CONCLUSIONS
153Sm-EDTMP is safe and effective for fast palliation of painful bone metastases and for inhibition of metastatic foci from breast cancer.
Wu
Haiming
H
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Tan
Tianzhi
T
Fang
Ling
L
Zhang
Xiying
X
D000328:Adult; D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology* / Q000532:radiotherapy; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010147:Pain Measurement; D010148:Intractable Pain / Q000188:drug therapy* / Q000209:etiology
D018712:Analgesics, Non-Narcotic; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; C061972:samarium Sm-153 lexidronam